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Introduction {#sec1}
============

CD6 is a lymphocyte membrane receptor characterized as being primarily expressed on T cells and some B cells. The extracellular region of CD6 contains three scavenger receptor cysteine rich (SRCR) domains and a membrane proximal stalk ([Figure 1](#fig1){ref-type="fig"}). CD6 engages in cell-cell interactions by binding to the immunoglobulin superfamily (IgSF) cell surface receptor, CD166, otherwise known as activated leukocyte adhesion molecule (ALCAM) ([@bib3; @bib7]) ([Figure 1](#fig1){ref-type="fig"}). CD166 is expressed more widely than CD6 and is found on both hematopoietic and nonhematopoietic cells ([@bib15]). In this *trans* interaction between cells, the membrane proximal SRCR domain of CD6 binds the N-terminal domain of CD166 ([@bib3]).

In addition to heterophilic interactions with CD6, CD166 also engages in homophilic interactions in *trans* between apposing cells ([@bib50; @bib53]) ([Figure 1](#fig1){ref-type="fig"}). As in binding CD6, homophilic interactions of CD166 depend on the N-terminal domain ([@bib8; @bib53]). Although weaker than the heterophilic CD6/CD166 interaction ([@bib22; @bib50]), CD166 homophilic interactions have pleiotropic effects and regulate not only normal but also neoplastic cells ([@bib15; @bib55]). Soluble fusion proteins of the extracellular regions of CD6 or CD166 inhibit T-cell responses ([@bib21; @bib22; @bib60]). A CD6 monoclonal antibody (mAb) against domain 3, characterized biochemically as blocking CD6/CD166 interactions distinguished between effects of heterophilic CD6/CD166 and homophilic CD166/CD166 interactions ([@bib23]). This mAb inhibited antigen-specific proliferation in a polyclonal population of human blood cells, revealing a costimulatory role for engagement of CD6 by CD166 ([@bib23]). The inhibitory effect of blocking extracellular engagement of CD6 and CD166 identifies these receptors as potential therapeutic targets for immunosuppression.

Costimulation by CD6 is dependent on phosphorylation of a C-terminal tyrosine motif which is specific for the adaptor protein, SLP-76 ([@bib23]). CD6 has an extraordinarily long cytoplasmic tail (244 amino acids) and provides an alternative to LAT as a scaffold for assemblies of signaling proteins in T cells ([@bib42]). In contrast, CD166 has a short cytoplasmic region that regulates adhesion through a link with the cytoskeleton ([@bib51]). Expression of CD6 raises the threshold of activation, and overall net inhibitory or costimulatory effects depend on the particular immune response being measured ([@bib23; @bib38]). The dual effects of CD6 make it difficult to interpret the consequences of SNPs that alter the expression of CD6 and correlate with susceptibility to multiple sclerosis ([@bib16; @bib24; @bib32; @bib49]).

It is not yet clear how the multiple domains of CD6 are important for function. In the absence of domain 3, no interaction with CD166 can be detected biochemically ([@bib8; @bib22]). However, CD6 domain 1 mAbs are inhibitory in cellular assays ([@bib32; @bib35; @bib44; @bib60]), and one has been recently licensed in India for use as an immunosuppressant for psoriasis ([@bib29]). Inhibition by a CD6 domain 1 mAb depends on the presence of CD6 domain 3, supporting the hypothesis that CD6 domain 1 mAbs perturb CD166/CD6 interactions between cells by steric hindrance ([@bib7; @bib32]).

Consecutive domains are a feature of group B members of the SRCR domain superfamily (reviewed in [@bib26]) with three consecutive group B SRCR domains found in the closely related cell surface proteins CD5 and CD6, and the soluble Apoptosis Inhibitor of Macrophages (AIM), also known by other names (Spα, CD5L), which comprises solely three consecutive SRCR domains. The involvement of multiple consecutive SRCR domains in ligand binding has been well characterized for the leukocyte surface receptor CD163, the second and third SRCR domains cooperating in ligand binding to hemoglobin/haptoglobin complexes ([@bib36]). All three SRCR domains contribute to ligand binding by AIM (Spα, CD5L), which was found to be associated with immunoglobulin M (IgM) in serum ([@bib2; @bib52]).

The crystal structure of CD6 is the first of consecutive SRCR domains, earlier structures being of single SRCR domains ([@bib20; @bib27; @bib41]). We reveal a nonlinear arrangement of the CD6 SRCR domains, which leads us to hypothesize about the roles of the individual domains and their different interactions.

Results {#sec2}
=======

Purification, Characterization, and Crystallization of CD6 and CD166 {#sec2.1}
--------------------------------------------------------------------

Recombinant His-tagged proteins of human CD6 SRCR domains 1--3 and human CD166 IgSF domains 1--3, i.e. the two N-terminal V domains and one C domain (CD166 VVC), were stably expressed in Lec 3.2.8.1 Chinese hamster ovary (CHO) cells ([@bib14]), purified, and deglycosylated. Protein crystals of the individual proteins were grown and diffraction data collected. We confirmed that the proteins used in this study interact as expected (data not shown and see [Supplemental Information](#app2){ref-type="sec"}) ([@bib9; @bib22]).

X-Ray Crystal Structure of CD6 Reveals a Nonlinear Organization of Consecutive SRCR Domains {#sec2.2}
-------------------------------------------------------------------------------------------

X-Ray diffraction data were collected to 3.15 Å and the structure solved by molecular replacement using a search model derived from the structure of a single SRCR domain of Mac-2 binding protein (PDB: [1BY2](pdb:1BY2){#intref0010}, 26.7% sequence identity to CD6 domain 1, 44.5% to CD6 domain 2, and 26.1% to CD6 domain 3; [@bib27]) ([Table 1](#tbl1){ref-type="table"}). The X-ray structure of CD6 is the first structure for a protein containing consecutive SRCR domains ([Figures 2](#fig2){ref-type="fig"}A and 2B).

The structure reveals a nonlinear organization of consecutive SRCR domains of CD6. Despite the interdomain interactions not being conserved, the orientations of each domain relative to its adjacent domain are very similar, both burying approximately 270 Å^2^. A consequence of this orientation at the interfaces between individual SRCR domains is a nonlinear consecutive domain structure, resulting in the three domains spanning 78.1 Å, a shorter distance than if the domains were in a linear arrangement ([Figures 2](#fig2){ref-type="fig"}A and 2B). This structural feature was also observed in a lower resolution dataset collected from a different crystal form (data not shown), supporting the idea that this is a biologically relevant structural feature. There is a disordered region in CD6 domain 1 in a similar position to a flexible loop in CD5 domain 1 ([@bib20]).

Mapping Domain 3 Mutants on the CD6 Structure Identifies the Ligand Binding Site for CD166 {#sec2.3}
------------------------------------------------------------------------------------------

Previous studies identified CD6 domain 3 and CD166 domain 1 as being sufficient to mediate ligand binding ([@bib8; @bib56]). The role of the other two CD6 SRCR domains in the heterophilic interaction is not clear. We quantified binding of soluble recombinant CD166 VVC to different forms of streptavidin-immobilized chimeric CD6 by surface plasmon resonance (SPR), in an attempt to detect any contribution of CD6 domains 1 and 2. No difference was detected in the binding of CD166 VVC to CD6, CD6 lacking domain 1, or CD6 lacking domains 1 and 2 ([Figure S1](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}).

Using our structure of CD6 and previous mutagenesis data ([@bib6; @bib47]), we carried out a more extensive mutagenesis study on CD6 domain 3 ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc1){ref-type="supplementary-material"}; see [Figure 4](#fig4){ref-type="fig"}A) to define the residues critical for CD166 binding. These data were mapped onto the structure, clearly identifying and defining the boundaries of the surface of CD6 that interacts with CD166. There is a high degree of amino acid conservation in this binding face between human, mouse, and rat CD6 sequences ([Figure 3](#fig3){ref-type="fig"}). Within this region amino acids have been identified that reduce binding to CD166, so it is likely that different species use the same face ([@bib9]) ([Figure 3](#fig3){ref-type="fig"}). We extended our previously published cross-species binding analysis to include rat CD6, and showed that human CD166 bound human, mouse, and rat CD6 with the same affinity ([@bib23] and data not shown).

Mapping Domain 1 Mutants on the X-Ray Crystal Structure of CD166 Identifies the Ligand Binding Site for CD6 {#sec2.4}
-----------------------------------------------------------------------------------------------------------

X-Ray diffraction data for crystals containing CD166 VVC were collected to 1.86 Å and the structure solved by molecular replacement with a search model derived from the second IgSF domain of RAGE (PDB: [3CJJ](pdb:3CJJ){#intref0015}, 16.4% sequence identity to domain 1 and 30.3% to domain 2; [@bib31]). Only the first two domains could be resolved in the electron density map ([Figures 2](#fig2){ref-type="fig"}C and 2D). The crystal lattice did not contain space to accommodate the third domain, suggesting it had been proteolytically cleaved prior to crystal growth.

We mapped previous mutagenesis data that defined residues in CD166 domain 1 critical for CD6 binding ([@bib45; @bib46]) onto the crystal structure ([Figures 2](#fig2){ref-type="fig"}D; [Table S3](#mmc1){ref-type="supplementary-material"}; see [Figure 4](#fig4){ref-type="fig"}B). This confirmed the prediction that binding to CD6 is mediated by the AGFCC′C″ face, in common with many other IgSF interactions ([@bib45; @bib46]). We repeated mutagenesis of five of these residues in CD166 domain 1 and confirmed that they all disrupted CD6/CD166 interactions ([Figure S3](#mmc1){ref-type="supplementary-material"}; [Table S3](#mmc1){ref-type="supplementary-material"}).

There Is Complementary Electrostatic Potential between CD166 and CD6 Binding Sites {#sec2.5}
----------------------------------------------------------------------------------

Mutagenesis of CD6 domain 3 ([@bib6; @bib47]) ([Table S2](#mmc1){ref-type="supplementary-material"} and [Figure 4](#fig4){ref-type="fig"}A: N346K, N348R, Q352R) showed that altering the charge from negative to positive in CD6 inhibited CD166 binding. Conversely, altering the charge from positive to negative in CD166 domain 1 ([Table S3](#mmc1){ref-type="supplementary-material"} and [Figure 4](#fig4){ref-type="fig"}B: K55E) inhibited binding to CD6 ([@bib45; @bib46]). Loss of charged amino acids ([Table S3](#mmc1){ref-type="supplementary-material"} and [Figure 4](#fig4){ref-type="fig"}B: E118A, K75A, D81A) in CD166 domain 1 also reduced binding, consistent with electrostatic potential being important for ligand binding. The calculated electrostatic potentials of the proposed interface between CD6 and CD166 are compatible with their interaction. The CD6 surface features a stripe of negative charge flanked with positive charge, and the CD166 surface features a complementary positively charged stripe flanked by negative charge ([Figure 4](#fig4){ref-type="fig"}).

Mapping Domain 1 mAb Epitopes on the CD6 Structure Shows How Ligand Binding between Cells Might Be Disrupted {#sec2.6}
------------------------------------------------------------------------------------------------------------

Inhibition by CD6 domain 1 mAbs has only been observed between cells, suggesting that intermembrane dimensions are important for their effects ([@bib8; @bib7]). To gain some insight from the CD6 structure as to how CD6 domain 1 mAbs might disrupt CD6/CD166 interactions, we mapped the epitope of a CD6 domain 1 mAb, MT605, which has been shown to inhibit immune responses between cells expressing CD6 and CD166 ([@bib32; @bib44; @bib60]). To identify the epitope, we produced alanine mutants of a number of surface-exposed residues in CD6 domain 1. Binding of MT605 was abolished by R77A ([Figure S4](#mmc1){ref-type="supplementary-material"}). Binding of another CD6 domain 1 mAb, MEM-98, was unaffected by R77A but was eliminated by E63A. MT605 was unaffected by E63A ([Figure S4](#mmc1){ref-type="supplementary-material"}). In the orientation shown in [Figure 2](#fig2){ref-type="fig"}, R77 lies at the top of CD6 domain 1. A large antibody binding in this position may prevent the close approach between cell membranes needed for CD6/CD166 engagement.

CD6 Nonsynonymous SNPs Associated with Multiple Sclerosis which Alter Expression Are Buried {#sec2.7}
-------------------------------------------------------------------------------------------

Of the SNPs identified in CD6, five alter amino acids in domains 2 and 3 ([Figure 5](#fig5){ref-type="fig"}). Homozygotes for two of these SNPs (R225W and A257V) in domain 2 have been associated with susceptibility to multiple sclerosis ([@bib49]). These two residues are buried within the domain and may disrupt the domain structure and stability of the molecule, explaining the correlation between reduced expression and susceptibility to multiple sclerosis.

The CD6 SNP, S351N, Results in Glycosylation that Disrupts CD6/CD166 Interactions {#sec2.8}
---------------------------------------------------------------------------------

Of the surface-exposed SNPs in CD6, the change from S351 to S351N found in 10% of the genomes analyzed (<http://www.1000genomes.org>) is the only residue close to the ligand binding site. We mutated CD6 S351 to S351N and compared the binding of soluble CD166 VVC to the two variants by SPR. CD166 VVC bound with a 10-fold weaker affinity to CD6 S351N compared with CD6 S351 ([Figure S5](#mmc1){ref-type="supplementary-material"}; [Table S5](#mmc1){ref-type="supplementary-material"}). Analysis of the kinetics of binding showed an increase in the dissociation rate of CD6 S351N compared with CD6 S351 ([Figure S5](#mmc1){ref-type="supplementary-material"}; [Table S4](#mmc1){ref-type="supplementary-material"}).

As S351N introduces a consensus N-linked glycosylation site (NQS), binding of CD166 may be sterically hindered by carbohydrate. There are seven consensus N-glycosylation sites in the three extracellular domains of CD6. In the recombinant protein, we observed electron density for GlcNAc attached to residue N229 in the second domain. There was no observable electron density for the other potential glycosylation sites in CD6. Mass spectrometry was used to determine whether recombinant CD6 S351N is glycosylated. As glycosylated peptides are not identified by liquid chromatography-tandem mass spectrometry due to the unknown mass of the N-linked carbohydrate, we quantified the precursor ion intensity obtained from extracted ion chromatograms of the FNNSNLCS~351~QSLAAR and FNNSNLCN~351~QSLAAR tryptic peptides before and after deglycosylation ([Figure S6](#mmc1){ref-type="supplementary-material"}; [Table S5](#mmc1){ref-type="supplementary-material"}). The S351 peptide was not glycosylated ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B), whereas the ion intensity of the S351N peptide was dependent on deglycosylation, showing that it was glycosylated ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). Consistent with the interpretation that S351N disrupted ligand binding by introducing a bulky carbohydrate moiety in proximity to the CD166 binding site, the CD6 mutant S351A restored binding, as measured by SPR ([Figure S5](#mmc1){ref-type="supplementary-material"}; [Table S5](#mmc1){ref-type="supplementary-material"}).

The glycosylation states of the other putative glycosylation sites in CD6 were determined qualitatively from the mass spectrometry data by comparing the number of peptide spectral matches of peptides containing each N-linked glycosylation site before and after deglycosylation with peptide-*N*-glycosidase F, showing that N28, N49, N229, and N351 are glycosylated and that N339 appears to be partially glycosylated ([Table S5](#mmc1){ref-type="supplementary-material"}).

Heterodimers Are Formed at the Expense of CD6 and CD166 Homodimers {#sec2.9}
------------------------------------------------------------------

Homophilic and heterophilic interactions of CD166 are mediated by the N-terminal domain. Mutations in the A′GFCC′C″ face, which disrupt CD6/CD166 interactions ([Figure 2](#fig2){ref-type="fig"}), map to the crystal contacts between the two N-terminal domains in the CD166 structure ([Figure 6](#fig6){ref-type="fig"}) ([@bib9]).

If the heterophilic and homophilic binding sites overlap, as implied by the CD166 crystal contacts, homophilic CD166 interactions would be disrupted by the formation of heterodimers with CD6. We examined the molecular species present when CD6 and CD166 were mixed in comparison with the individual components by native mass spectrometry. When CD6 and CD166 were analyzed separately, we found that both CD6 and CD166 were predominantly in monomer-dimer equilibrium ([Figures 7](#fig7){ref-type="fig"}A and 7B). When CD6 and CD166 were mixed, there was an increase in the relative abundance of heterodimers, a corresponding decrease of the CD6 and CD166 monomers, and a complete depletion of homodimers when compared with the unmixed samples ([Figure 7](#fig7){ref-type="fig"}C). These data show that heterodimers are formed at the expense of CD6 and CD166 homodimers. Due to the heterogeneity in molecular masses caused by glycosylation, the collision voltage on the mass spectrometer was increased to achieve more accurate mass determination, and these experimentally calculated masses are shown in [Table 2](#tbl2){ref-type="table"}. The mass of the heterodimer was confirmed by analysis of its composition by tandem mass spectrometry (data not shown).

Comparison of the molecular species identified in native mass spectrometry and multi-angled light scattering also revealed a dynamic equilibrium between the different species ([Figure S7](#mmc1){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

The structures of CD6 and CD166 give insight into the heterophilic CD6/CD166 and homophilic CD166/CD166 interactions and those of other proteins containing consecutive SRCR domains. The structure of CD6 is the first for proteins containing consecutive SRCR domains. One striking feature is the nonlinear domain organization, which has implications for the topology and orientations of interactions with individual domains.

The Role of Consecutive SRCR Domains in CD6/CD166 Interactions {#sec3.1}
--------------------------------------------------------------

The relatively high affinity *trans* interaction between CD6 and CD166 on apposing cells is mediated by the CD6 membrane proximal domain. The main contribution of the other two CD6 SRCR domains to the CD6/CD166 interaction may be to regulate accessibility of CD166 to the membrane proximal domain of CD6, as formation of CD6/CD166 heterodimers involves competition with the homophilic CD166 interactions. *Trans* CD166 homophilic interactions were inhibited by preventing clustering in *cis* on the cell surface with an antibody specific for the membrane proximal domains of CD166 or by a dominant negative mutant lacking the N-terminal domain ([@bib53; @bib54; @bib55]). Weak interactions in *cis* between the membrane proximal domains of CD166 at the cell surface may enhance homophilic adhesion in *trans* ([@bib53; @bib59]). The projection of CD6 domain 1, which results from the nonlinear domain organization, may be important for preventing clustering of CD166 at the cell surface, and may provide an additional steric hindrance mechanism to disrupt the CD166 *trans* homodimers between cells.

The topology of the CD6 SRCR domains shows how CD6 domain 1 mAbs might impede access of CD166 to the membrane proximal domain of CD6 between cells ([@bib7; @bib32]). Inhibition of the CD6/CD166 interaction by CD6 domain 1 mAbs has only been observed between cells and is likely to be dependent on the level of CD6/CD166 engagement ([@bib7; @bib13; @bib32; @bib44; @bib60]).

The main role of domain 2 of CD6 may be as a spacer to maintain the projection of CD6 domain 1. However, in the characterization of an interaction between the SRCR domains of the closely related protein CD5 and the V region of the heavy chain of immunoglobulin, first reported in rabbit, only the isolated domain 2 of human CD5 was capable of binding the V region of the heavy chain of human immunoglobulin ([@bib40]). CD5 differs in topology from CD6 in containing a proline-rich linker between domains 1 and 2 that may be important for accessibility to domain 2.

A subsidiary role for domains other than CD6 domain 3 and CD166 domain 1 in CD6/CD166 interactions, which are below the detection limit of SPR analysis, cannot be completely ruled out, as there are data suggesting weak interactions of other domains in high-avidity binding assays ([@bib8]). In the context of a lattice formation between cells ([@bib55]), a very low-affinity interaction may be productive ([@bib59]). CD6 domain 2 may be important for divalent cation-dependent interactions of CD6, as it contains a conserved triacidic motif D187/D188/E253 ([@bib36]). CD6/CD166 interactions occur in the absence of divalent cations ([@bib22; @bib39]; L.I.G., unpublished data).

Homodimers of CD166 and also CD6 were detected in native mass spectrometry ([Figure 7](#fig7){ref-type="fig"}). When mixed, the main species was heterodimers of CD6 and CD166. Based on data for CD5, CD6 homodimers are more likely to form in *cis* on the same cell surface ([@bib4; @bib11]). The nonlinear arrangement of the SRCR domains in CD6 is compatible with individual domains engaging in interactions in different orientations. If the angle of projection of CD6 from the cell surface is as depicted in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, it places the N-terminal domain in a position that could be important for creating contacts on the same cell surface, including homophilic interactions. Deletion of the N-terminal domain of CD6 resulted in a protein that was not stable at the cell surface, whereas CD6 containing domain 1 but lacking the membrane proximal domain is expressed stably at the cell surface ([@bib13; @bib32]; M.H.B., unpublished data). Dimerization of CD6 might be important for stabilization at the surface in the absence of ligand binding, and ligand engagement by CD166 may be important for stabilizing CD6 monomers at the cell surface to maintain immune responses ([@bib60]).

Heterophilic CD6/CD166 and Homophilic CD166/CD166 Interactions {#sec3.2}
--------------------------------------------------------------

In the competition between CD6 domain 3 and the N-terminal domain of CD166, heterodimers are formed at the expense of the weaker homophilic interactions of CD166 ([@bib22; @bib50]; and see above). Crystal contacts in the CD166 structure suggest that the sites for heterophilic and homophilic binding on CD166 domain 1 overlap ([Figure 6](#fig6){ref-type="fig"}). Alternatively, heterophilic and homophilic interactions may compete through steric hindrance.

The structures of the interacting domains, the membrane proximal domain of CD6, domain 3, and the N-terminal domain of CD166 showed that mutants that disrupt binding to CD166 cluster together on the surface of CD6 ([@bib6; @bib47]), identifying the binding face on domain 3. Complementary mapping of mutants of CD166 that affected ligand binding delineated the binding site predicted to be on the A′GFCC′C″ face of the CD166 structure ([@bib6; @bib47]).

The binding faces of CD6 SRCR domain 3 and CD166 domain 1 are predominantly positively and negatively charged, respectively ([Figure 4](#fig4){ref-type="fig"}) ([@bib9]). Ligand binding by SRCR domains in MARCO and CD163, in groups A and B, respectively, involves complementarity in charge ([@bib36; @bib37]). Electrostatic potential is likely to be important in the CD6/CD166 interaction.

Implications for Other Proteins Containing Consecutive SRCR Domains {#sec3.3}
-------------------------------------------------------------------

The interaction between CD6 and CD166 functions in the adaptive immune system, whereas the majority of SRCR superfamily domains are found in the innate immune system ([@bib26]). Preservation of the three consecutive SRCR domains may be important for maintaining more promiscuous low-affinity interactions ([@bib1; @bib2]) with ligand binding depending on avidity with contributions from each domain, as has been observed in the interaction between AIM (Spα, CD5L) and IgM ([@bib2]). There may be a similar nonlinear domain arrangement in other proteins containing consecutive SRCR domains that is important for multiple domains making contact with a ligand. Modeling the conformation of longer arrays of SRCR domains with similar length linker sequences suggests that these proteins would form a helical structure.

Group A SRCR domains containing proteins that consist of polypeptides with single SRCR domains trimerize, which may create an alternative topology for multivalent binding. There is a model based on a crystal structure for how membrane distal single SRCR domains of MARCO multimerize to form a large ligand binding face for pathogens ([@bib37]). Direct pathogen binding has been described for several SRCR domains, including CD6 ([@bib43]). A bacterial binding peptide motif was first identified in an SRCR domain of DMBT1, otherwise known as salivary agglutinin ([@bib5; @bib33]). A consensus sequence for this bacterial binding peptide is found in CD6 SRCR domain 2 ([@bib5]). Examining the position of this peptide on the structure of CD6, the region is predominantly surface exposed and is on the opposite face to the CD166 binding site. Its significance is uncertain. Mutation of this consensus sequence in the SRCR domain protein WC1 did not affect bacterial binding ([@bib28]).

Effects of Single Polymorphisms in CD6 {#sec3.4}
--------------------------------------

Selection pressure for nonsynonymous SNPs in CD6 domain 2 that are associated with susceptibility to multiple sclerosis ([Figure 5](#fig5){ref-type="fig"}) may simply be to reduce expression levels ([@bib49]). Reduced expression levels will lower both the threshold of activation and ligand engagement ([@bib23]). The strongest association of a SNP in CD6 with disease susceptibility is in an intron, and correlates with a reduced ratio of expression of full-length CD6 compared with a form of CD6 which lacks the ligand binding domain, suggesting that the dominant effect is mediated by decreased ligand binding ([@bib13; @bib32]). Disease association for the less common SNP, S351N, which has reduced affinity for CD166, has not yet been reported. Mutagenesis and mass spectrometric analysis provided evidence that reduced binding was due to glycosylation of CD6 at S351N. We assume this high frequency SNP is likely to be associated with subtle functional changes in CD6 activity.

Topology of CD6/CD166 Interactions {#sec3.5}
----------------------------------

On engagement by CD166, CD6 has been observed to move into areas of close contact between T cells and antigen-presenting cells ([@bib13; @bib21; @bib60]), suggesting that the interacting receptors will match the dimensions of the T-cell receptor and other receptors observed to colocalize, ∼140 Å ([@bib17]) ([Figure 2](#fig2){ref-type="fig"}). The nonlinear domain structure may be important for accommodating CD6 in areas of close apposition between cells. The nonlinear structure of the three SRCR domains spans 78.1 Å. This excludes the 37 amino acid membrane proximal stalk region of unknown dimensions. The two IgSF V domains of CD166 span 90.4 Å, comparable with the dimensions of the two IgSF V domains in another cell surface receptor, JAM (86 Å, PDB: [1F97](pdb:1F97){#intref0025}). Extrapolating from the dimensions of the two CD166 IgSF V and three C domains taking the size of a C domain to be 35 Å from human CD2 domain 2 (PDB: [1HNG](pdb:1HNG){#intref0030}), the five domains in a linear array would be predicted to span ∼200 Å. This suggests there is flexibility and/or deviation from the perpendicular by CD166 between apposing cells to optimize formation of *trans* interactions, as has been proposed for five domain E-cadherins ([@bib59]). If the parallel, as distinct from anti-parallel orientation of the interacting CD166 N-terminal domains, is physiological, it will restrict the dimensions of homophilic *trans* interactions ([@bib51; @bib53]). Determination of the X-ray crystal structures of CD6 and CD166 allows us to create a more accurate model of how these proteins regulate interactions at the cell surface, and to design the most effective therapeutic reagents.

Experimental Procedures {#sec4}
=======================

Recombinant Proteins for Crystallization {#sec4.1}
----------------------------------------

Three human CD6 (GenBank: [U34623](ncbi-n:U34623){#intref0035}; UniProt: [P30203](uniprotkb:P30203){#intref0040}) SRCR domains (residues 1--364) and two V-like domains and one C-like domain (VVC) (residues 1--335) of human CD166 (UniProt: [Q13740](uniprotkb:Q13740){#intref0045}) were amplified from plasmid DNA ([@bib8]) and expressed as endoglycosidase H sensitive His-tagged proteins (CD6; LCSASRGHHHHHH CD166; YLDLSTRHHHHHH) containing their native leader sequences using PEE14 vector in CHO Lec 3.2.8.1 cells ([@bib14]). CHO cell lines selected for stable expression were grown in cell factories to confluence; sodium butyrate (2 mM) was then added and the cells were allowed to secrete for 2--3 weeks before harvesting. Tissue culture supernatant was concentrated (Sartorius Vivablock, molecular weight cutoff 10 kDa) and proteins purified using nickel chromatography columns (NiNTA, Qiagen) and elution with an imidazole gradient in 10 mM HEPES, 150 mM NaCl (pH 7.4). Proteins were immediately dialyzed to remove imidazole and then subjected to size-exclusion chromatography (Superdex200 column; GE Healthcare). For crystallization, proteins were deglycosylated with EndoHf (New England Biolabs), 0.3--2.5 U/ml in 10 mM HEPES, 150 mM NaCl (pH 7.4) at 37°C for 2 hr and analyzed by SDS-PAGE.

Crystallization {#sec4.2}
---------------

The three extracellular SRCR domains of human CD6 were crystallized using the sitting drop method in 0.1 M ammonium sulfate, 0.3 M sodium formate, 0.1 M sodium cacodylate, 3% w/v PGA-LM, 20% MPD (pH 6.5) at 20°C. Drops were set up using 2.5 μl of a protein solution containing a complex of CD6 and CD166 at an OD~280~ of 2.22, and 2.5 μl of the reservoir solution. CD6 crystals grew within 4 weeks.

The two membrane distal immunoglobulin domains of human CD166 were crystallized using the sitting drop method in 0.1 M sodium HEPES (pH 7.5) and 25% w/v PEG-2000 MME. Drops were set up using 2 μl of a protein solution containing CD166 domains 1--3 at an OD~280~ of 4.58. Crystals grew after 4 weeks. Crystals were flash-frozen in liquid nitrogen and data were collected at the Diamond Light Source, Harwell, at 100 K on beamline i04-1.

Data Collection and Processing {#sec4.3}
------------------------------

Native datasets were collected for CD6 and CD166, to 3.15 Å and 1.86 Å, respectively. The data were integrated and scaled using XDS ([@bib30]) and aimless ([@bib19]) as implemented in XIA2 ([@bib58]). Molecular replacement search models were generated using CHAINSAW ([@bib48]), and large loops removed. The structure of human CD6 was solved by searching for three copies of a search model derived from the Mac2 binding protein, a single SRCR domain (PDB: [1BY2](pdb:1BY2){#intref0050}; [@bib27]) using PHASER ([@bib34]), part of the CCP4 software suite ([@bib57]). The human CD166 structure was solved by searching with a search model derived from the second immunoglobulin domain in the ligand binding domain of human RAGE (PDB: [3CJJ](pdb:3CJJ){#intref0055}; [@bib31]). Model building and refinement were carried out using Coot ([@bib18]) and AUTOBUSTER ([@bib10]). The CD6 and CD166 structures were refined to *R*~work~/*R*~free~ of 0.25/0.28 and 0.22/0.24, respectively. Coordinates were deposited in the PDB (PDB: [5a2e](pdb:5a2e){#intref0060} for CD6 and PDB: [5a2f](pdb:5a2f){#intref0065} for CD166).

Native Mass Spectrometry {#sec4.4}
------------------------

Purified CD6 and CD166, along with a mixture of both proteins, were subjected to native mass spectrometry analysis. Proteins were at a concentration of 20 μM and the mixture formed by incubating an equal amount of CD6 and CD166 (both at 20 μM) for 30 min at room temperature. Samples were buffer exchanged from 10 mM HEPES, 150 mM NaCl (pH 7.4) into 250 mM ammonium acetate (pH 7.6) using Biospin-6 columns (Bio-Rad). Mass spectrometry measurements were carried out on a modified Synapt G1 HDMS (Waters Corp.) Q-ToF mass spectrometer ([@bib12]). The instrument was mass calibrated using a solution of 10 mg/ml cesium iodide in water. Aliquots (2 μl) of samples were delivered to the mass spectrometer by means of nano-electrospray ionization via gold-coated capillaries, prepared in-house ([@bib25]). Instrumental parameters were as follows: source pressure 5.6 mbar, capillary voltage 1.20 kV, cone voltage 50 V, trap energy 10 V, bias voltage 5 V, and trap pressure 1.63 × 10^−2^ mbar. The trap energy was increased to 30 V to obtain more accurate mass measurements.
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====================
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![Heterophilic and Homophilic Interactions of CD6 and CD166 between Cells\
CD6 contains three SRCR domains (Sc, squares) and CD166 contains five IgSF domains (two V and three C2). The membrane proximal domain of CD6 binds the N-terminal immunoglobulin superfamily (IgSF) domain (oval) of CD166.](gr1){#fig1}

![Structures of CD6 and CD166 Identify a Binding Interface and Reveal a Nonlinear Arrangement of Domains in CD6\
(A and C) Cartoon diagrams colored from blue at the N terminus to red at the C terminus.\
(B and D) Surface representations, with mutations in CD6 affecting ligand binding colored red.\
Similar interdomain orientations of CD6 domains result in an overall nonlinear organization. A disordered loop exists in the N-terminal domain of CD6. Binding of CD6 domain 1 mAb MT605 was specifically reduced by R77A mutation (see [Figure S4](#mmc1){ref-type="supplementary-material"}).](gr2){#fig2}

![CD6 SRCR Domains, Residues 43--364, which Bind CD166 Are Conserved Across Species\
Human (UniProt: [P30203](uniprotkb:P30203){#intref0075}), mouse (UniProt: [Q61003](uniprotkb:Q61003){#intref0080}), and rat (UniProt: [Q5FVU4](uniprotkb:Q5FVU4){#intref0085}) CD6 bind human CD166 ([@bib23] and data not shown). Compared with CD6 SRCR domain 3, which binds CD166, CD6 domains 1 and 2 have more variation in amino acid sequence between human, mouse, and rat CD6.](gr3){#fig3}

![Complementary Electrostatic Potential between CD166 and CD6 Binding Faces\
Surface representations of human CD6 (A) and human CD166 (B) displaying electrostatic potential (negative charge in red and positive charge in blue) and mutations that do not affect binding (green) and that affect binding (red). Areas of complementary electrostatic potential are outlined with a dotted line.](gr4){#fig4}

![Nonsynonymous SNPs in CD6 Associated with Disease Are Not in the CD166 Binding Site\
SNPs are mapped on the structure of CD6 and displayed as spheres.](gr5){#fig5}

![Crystal Contacts Identify a Potential CD166 Domain 1 Homophilic Binding Face\
Cartoon representations colored from blue at the N-terminus to red at the C-terminus (A) and surface representations (B) of CD166 domains 1 and 2, showing a binding interface between the A′GFCC′C″ faces ([@bib9]). The homophilic interface is outlined in black (C).](gr6){#fig6}

![Heterodimers Are Formed at the Expense of CD6 and CD166 Homodimers\
Native mass spectrometry data are shown for the CD6 (A) and CD166 (B) proteins separately, and for the CD6/CD166 mixture (C). The CD6 and CD166 proteins exist predominantly in a monomer-dimer equilibrium. Charge state series are indicated with circles: gray and red for CD6 monomer and dimer; and black and green for CD166 monomer and dimer, respectively. In the mixture (C), the CD6/CD166 heterodimer, indicated with blue circles, is the most abundant species. Smaller amounts of individual CD6 and CD166 monomers, colored in cyan, also exist. Where more than one mass was found for a species due to glycosylation, only the most abundant one is indicated on the spectra for clarity. All experimentally calculated masses can be found in [Table 2](#tbl2){ref-type="table"}.](gr7){#fig7}

###### 

Crystallographic Data for CD6 and CD166

                                                              CD6                                    CD166
  ----------------------------------------------------------- -------------------------------------- --------------------------------------
  **Data Collection**                                                                                
                                                                                                     
  X-Ray source                                                Diamond Light Source, beamline i04-1   Diamond Light Source, beamline i04-1
  Wavelength (Å)                                              0.92                                   0.92
  Resolution range (Å)                                        77.93--3.15 (3.23--3.15)               51.14--1.86 (1.91--1.86)
  Space group                                                 P 63 2 2                               P 43 21 2
  Unit Cell                                                                                          
  a, b, c (Å)                                                 161.48, 161.48, 93.85                  72.32, 72.32, 105.04
  α, β, γ (°)                                                 90, 90, 120                            90, 90, 90
  Total reflections                                           69,680 (5,176)                         313,66 (22,938)
  Unique reflections                                          12,884 (933)                           24,110 (1,731)
  Multiplicity                                                5.4 (5.5)                              13.0 (13.3)
  Completeness (%)                                            99.6 (99.8)                            99.9 (99.9)
  Mean *I*/σ(*I*)                                             7.2 (2.2)                              20.1 (3.8)
  *R*~merge~ (all I^+^ and I^−^) (%)                          23.2 (80.0)                            8.0 (65.9)
                                                                                                     
  **Refinement**                                                                                     
                                                                                                     
  Resolution range (Å)                                        77.93--3.15                            21.09--1.86
  No. of reflections (work/test set)                          12,883/629                             24,029/1,229
  No. of atoms (protein, glycans, ligands, waters)            4,399, 27, 60, 43                      3,496, 54, 160, 186
  Protein residues                                            324                                    218
  Mean B-factors (protein, glycans, ligands, waters) (Å^2^)   37.85, 61.24, 35.33, 10.28             32.53, 47.28, 59.05, 38.80
  *R*~work~ (%)                                               25.31                                  22.17
  *R*~free~ (%)                                               28.31                                  23.91
  Rmsd from ideal values (bonds, Å)                           0.0061                                 0.0061
  Rmsd from ideal values (angles, °)                          0.76                                   0.93
  Ramachandran plot                                                                                  
  Favored regions (%)                                         95.05                                  96.79
  Outliers (%)                                                0                                      0

Rmsd, root-mean-square deviation.

###### 

Calculated Mass Species of CD6 and CD166 from Native Mass Spectrometry

                  Experimentally Calculated Mass (Da)   Standard Deviation (Da)
  --------------- ------------------------------------- -------------------------
  **CD6**                                               
                                                        
  Monomer 1       44,509                                ±3
  Monomer 2       45,721                                ±4
  Dimer 1         89,135                                ±13
  Dimer 2         90,173                                ±16
  Dimer 3         91,436                                ±13
                                                        
  **CD166**                                             
                                                        
  Monomer 1       39,751                                ±8
  Monomer 2       40,139                                ±12
  Monomer 3       40,975                                ±4
  Monomer 4       41,198                                ±6
  Dimer 1         80,045                                ±9
  Dimer 2         81,046                                ±24
  Dimer 3         82,112                                ±24
                                                        
  **CD6/CD166**                                         
                                                        
  Dimer 1         84,557                                ±40
  Dimer 2         85,592                                ±32
  Dimer 3         86,770                                ±24
